Paid Clinical Trials and Focus Groups by Location |
|
|
|
Conditions: Chronic Kidney Disease; Medication Adherence
Intervention: Device: Electronic Pillbox Monitoring System
Sponsor: Harvard Pilgrim Health Care
Recruiting - verified March 2010
Conditions: Cardiovascular Disease; Obstructive Sleep Apnea; Coronary Artery Disease
Interventions: Other: Healthy Lifestyles and Sleep Education plus PAP; Other: Healthy Lifestyles and Sleep Education plus Supplemental Oxygen; Other: Healthy Lifestyles and Sleep Education
Sponsors: University Hospitals of Cleveland; Case Western Reserve University; Partners HealthCare; Johns Hopkins University; VA Boston Healthcare System
Recruiting - verified March 2010
Condition: Tobacco Use
Intervention: Other: Exposure to practice that has been trained in Pedialink CEASE
Sponsors: Massachusetts General Hospital; Flight Attendant Medical Research Institute
Recruiting - verified March 2010
Condition: Sickle Cell Disease
Intervention: Drug: Lexiscan
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Children's Hospital Boston; Washington University School of Medicine; LaJolla Institute for Allergy and Immunology; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified March 2010
Condition: Pregnant Women With Peripartum Cardiomyopathy
Intervention:
Sponsors: University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified March 2010
Condition: Multiple Sclerosis
Intervention: Drug: Rebif
Sponsor: EMD Serono
Not yet recruiting - verified March 2010
Conditions: Depression; Major Depressive Disorder
Interventions: Drug: F2695 SR; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified March 2010
Condition: Chronic Hepatitis C
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Device: autoinjector; Device: pre-filled syringe
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified March 2010
Condition: Hypertension
Intervention: Other: Computerized reminders on hypertension intensification
Sponsors: Brigham and Women's Hospital; Robert Wood Johnson Foundation
Not yet recruiting - verified March 2010
Conditions: Schizophrenia; Schizoaffective Disorders; Schizophreniform Disorders
Interventions: Drug: Pravastatin; Drug: Placebo
Sponsors: Massachusetts General Hospital; Stanley Medical Research Institute
Not yet recruiting - verified March 2010
Condition: Insulin Resistance
Intervention:
Sponsors: Children's Hospital Boston; University of Massachusetts
Recruiting - verified March 2010
Condition: Diabetes
Intervention:
Sponsor: Beth Israel Deaconess Medical Center
Recruiting - verified March 2010
Condition: Acute Gout
Interventions: Drug: ACZ885; Drug: Triamcinolone acetonide
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Polycystic Ovary Syndrome
Intervention: Behavioral: Nutrition Education, Dietary Counseling, and Cooking
Sponsors: Children's Hospital Boston; Thrasher Research Fund
Not yet recruiting - verified March 2010
Condition: Melanoma
Interventions: Drug: bortezomib; Drug: sorafenib
Sponsors: Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital; Brigham and Women's Hospital; Bayer; Millennium Pharmaceuticals, Inc.
Not yet recruiting - verified March 2010
Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA); National Institutes of Health (NIH)
Not yet recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: Indacaterol dose; Drug: Placebo; Drug: Salmeterol
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Osteoarthritis, Knee
Intervention: Device: acupuncture
Sponsors: Massachusetts General Hospital; National Center for Complementary and Alternative Medicine (NCCAM); Harvard University; Brigham and Women's Hospital
Recruiting - verified March 2010
Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: pomalidomide; Drug: dexamethasone; Drug: rituximab
Sponsors: Dana-Farber Cancer Institute; Celgene Corporation
Not yet recruiting - verified March 2010
Condition: Fibromyalgia
Interventions: Drug: Placebo; Drug: Milnacipran
Sponsors: Forest Laboratories; Cypress Bioscience, Inc.
Recruiting - verified February 2010
Condition: Arthritis, Psoriatic
Interventions: Drug: ustekinumab; Drug: placebo; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Not yet recruiting - verified February 2010
Condition: Allergic Rhinitis
Interventions: Drug: Fluticasone Furoate Nasal Spray; Drug: Olopatadine Nasal Spray; Drug: Saline Nasal Spray
Sponsor: ORA, Inc.
Not yet recruiting - verified February 2010
Conditions: Obsessive Compulsive Disorder; Body Dysmorphic Disorder; Tourette Syndrome; Trichotillomania; Panic Disorder; Social Phobia; Generalized Anxiety Disorder; Depression; Post-Traumatic Stress Disorder; Attention Deficit Hyperactivity Disorder; Eating Disorder
Intervention: Behavioral: Cognitive behavioral therapy (CBT)
Sponsor: Massachusetts General Hospital
Recruiting - verified February 2010
Conditions: Non-small Cell Lung Cancer; EGFR Mutations
Intervention: Drug: BIBW 2992
Sponsors: Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Boehringer Ingelheim Pharmaceuticals
Not yet recruiting - verified February 2010
Condition: Diabetes Mellitus
Interventions: Device: Finesse; Device: Pen/Syringe (Usual injection device)
Sponsors: Calibra Medical, Inc.; Nancy Bohannon, MD, Med. Corp.; Henry Ford Health System; Northwestern University; University of Texas Southwestern Medical Center; Joslin Diabetes Center; International Diabetes Center at Park Nicollet
Recruiting - verified March 2010
Condition: Pregnancy Outcome Trends in Low-resource Geographic Areas
Intervention: Other: There is no intervention associated with this study.
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 2009
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Placebo; Drug: Tiotropium
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
Conditions: Sedentary Lifestyle; Risk of Disability; Aging
Intervention: Behavioral: Lifestyle modification
Sponsors: University of Florida; National Institute on Aging (NIA); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Conditions: Acute Lung Injury; Adult Respiratory Distress Syndrome
Intervention:
Sponsor: Boston Medical Center
Not yet recruiting - verified February 2010
Condition: Corneal Neovascularization
Interventions: Drug: Avastin (bevacizumab); Drug: 0.9% NaCl
Sponsor: Massachusetts Eye and Ear Infirmary
Recruiting - verified December 2009
Condition: PTSD
Intervention: Other: Supported Education
Sponsor: Department of Veterans Affairs
Not yet recruiting - verified February 2010
Condition: Exercise Induced Asthma
Interventions: Drug: Budesonide/Formoterol; Drug: Budesonide
Sponsors: Children's Hospital Boston; Brigham and Women's Hospital
Recruiting - verified February 2010
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: natalizumab; Drug: interferon beta 1-a; Drug: methylprednisolone; Other: IV placebo; Drug: glatiramer acetate
Sponsors: Biogen Idec; Elan Pharmaceuticals
Not yet recruiting - verified February 2010
Condition: Septic Shock
Interventions: Drug: D5W; Drug: Thiamine
Sponsors: Beth Israel Deaconess Medical Center; National Institutes of Health (NIH); National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified February 2010
Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Elan Pharmaceuticals
Not yet recruiting - verified February 2010
Conditions: Hyperphosphatemia; End-Stage Renal Disease
Intervention: Drug: ferric citrate
Sponsor: Keryx Biopharmaceuticals
Not yet recruiting - verified February 2010
Condition: Peanut Allergy
Intervention: Drug: Trichuris suis ova (TSO)
Sponsors: Beth Israel Deaconess Medical Center; Food Allergy Initiative
Recruiting - verified February 2010
Condition: Diabetic Foot Ulcers
Interventions: Drug: MEBO Wound Ointment (MEBO); Drug: Sterile Saline Moistened Gauze
Sponsor: Skingenix, Inc.
Not yet recruiting - verified February 2010
Conditions: Type 2 Diabetes Mellitus; Obesity
Interventions: Procedure: Laparoscopic Adjustable Gastric Band; Procedure: Roux-en-Y Gastric Bypass (Surgery); Other: Intensive Medical Diabetes & Weight Management; Device: Allergan Adjustable Gastric Band
Sponsors: Joslin Diabetes Center; Brigham and Women's Hospital
Recruiting - verified February 2010
Condition: Intra-abdominal Infection
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Ertapenem, Amoxicillin/clavulanate
Sponsor: Bayer
Not yet recruiting - verified March 2010
Conditions: Breast Cancer; Diagnostic Imaging
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsor: Bayer
Recruiting - verified March 2010
Conditions: Wegener's Granulomatosis; Microscopic Polyangiitis; Churg Strauss Syndrome; Polyarteritis Nodosa; Giant Cell Arteritis; Takayasu Arteritis
Intervention:
Sponsors: University of Oxford; American College of Rheumatology; The European League Against Rheumatism (EULAR); The Vasculitis foundation
Not yet recruiting - verified February 2010
Conditions: Hypertension, Pulmonary; Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Not yet recruiting - verified March 2010
Condition: Obesity
Intervention: Other: Liquid test meal
Sponsors: Beth Israel Deaconess Medical Center; Children's Hospital Boston; Brigham and Women's Hospital
Recruiting - verified February 2010
Conditions: Diabetic Neuropathy, Painful; Diabetic Polyneuropathy
Interventions: Drug: Oxycodone controlled release (CR); Drug: Tapentadol extended release (ER)
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Grünenthal GmbH
Recruiting - verified February 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: simvastatin; Drug: Placebo
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Condition: Myelodysplastic Syndrome
Interventions: Drug: Ezatiostat Hydrochloride; Drug: Lenalidomide (Revlimid®)
Sponsor: Telik
Recruiting - verified February 2010
Condition: Influenza
Interventions: Biological: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A; Biological: GSK Biologicals' FluLaval®; Biological: Placebo (saline); Biological: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Post-transplant Lymphoproliferative Disease; Solid Organ Transplant; Stem Cell Transplant (Bone Marrow Transplant); Epstein Barr Virus Infections
Interventions: Drug: bortezomib; Drug: rituximab
Sponsors: Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Millennium Pharmaceuticals, Inc.
Not yet recruiting - verified February 2010
Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Infantile Hemangioma
Interventions: Drug: Propranolol; Drug: Placebo
Sponsor: Pierre Fabre Dermatology
Recruiting - verified March 2010
Conditions: Vaginosis, Bacterial; Vaginal Infection
Interventions: Drug: GW05; Drug: GW05; Drug: GW05; Drug: Metronidazole
Sponsor: Graceway Pharmaceuticals, LLC
Recruiting - verified March 2010
Conditions: Iron Deficiency; Anemia; Kidney Disease
Interventions: Drug: ferumoxytol; Drug: iron sucrose
Sponsor: AMAG Pharmaceuticals, Inc.
Recruiting - verified February 2010
Conditions: Schizophrenia; Bipolar Disorder; Autistic Disorder; Attention Deficit and Disruptive Behavior Disorders
Interventions: Drug: Other atypical antipsychotic drugs; Drug: Risperidone
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Conditions: Pulmonary Disease, Chronic Obstructive; Chronic Obstructive Pulmonary Disease
Interventions: Drug: FF/GW642444 Inhalation Powder; Drug: Placebo; Drug: FF Inhalation Powder; Drug: GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Parkinson's Disease
Interventions: Drug: Rasagiline; Drug: Placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified March 2010
Conditions: Liver Metastases; Liver Cancer
Intervention: Biological: rRp450
Sponsors: Massachusetts General Hospital; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aclidinium bromide/formoterol fumarate combination; Drug: aclidinium bromide/formoterol fumarate combination; Drug: aclidinium bromide; Drug: formoterol fumarate; Drug: placebo
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: sitagliptin
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN5401; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified February 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide; Drug: Aclidinium bromide; Drug: Placebo
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Conditions: Acute Coronary Syndrome; Myocardial Infarction; Unstable Angina Pectoris
Intervention: Radiation: Cardiac Computed Tomography
Sponsor: Massachusetts General Hospital
Not yet recruiting - verified March 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aclidinium bromide; Drug: aclidinium bromide
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Condition: Diabetic Macular Edema
Intervention: Biological: MP0112
Sponsor: Molecular Partners AG
Recruiting - verified March 2010
Condition: Familial Amyotrophic Lateral Sclerosis
Intervention: Drug: ISIS 333611
Sponsors: Isis Pharmaceuticals; Muscular Dystrophy Association; ALS Association
Recruiting - verified February 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Disease-modifying antirheumatic drug
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Acute Lung Injury; Adult Respiratory Distress Syndrome
Interventions: Other: low-tidal-volume ventilation; Other: APRV
Sponsors: Boston Medical Center; Department of Defense
Not yet recruiting - verified February 2010
Condition: Painful Diabetic Neuropathy
Interventions: Drug: GRT3983Y; Drug: Placebo
Sponsor: Grünenthal GmbH
Recruiting - verified February 2010
Condition: Chronic Low Back Pain
Interventions: Drug: EN3324; Drug: Placebo
Sponsor: Endo Pharmaceuticals
Recruiting - verified March 2010
Condition: Alzheimer's Disease
Intervention: Drug: Semagacestat
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Condition: Hepatitis C Virus
Interventions: Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: Peginterferon Alfa-2a; Drug: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Blood Coagulation Disorders; Hemophilia A
Interventions: Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973); Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973); Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973)
Sponsor: Bayer
Recruiting - verified March 2010
Conditions: Dry Eye Syndromes; Keratoconjunctivitis Sicca
Interventions: Drug: rebamipide 2% ophthalmic suspension; Drug: placebo eye drops
Sponsors: Acucela Inc.; Otsuka Pharmaceutical Co., Ltd.
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Drug: MPC-4326 plus a 2-3 drug optimized background regimen (OBR); Drug: 3-4 commercially available antiretroviral drugs
Sponsor: Myriad Pharmaceuticals
Recruiting - verified March 2010
Conditions: Open-Angle Glaucoma; Ocular Hypertension
Interventions: Drug: Preservative-Free MK2452 (Tafluprost); Drug: Comparator: timolol
Sponsor: Merck
Recruiting - verified March 2010
Conditions: Neuroendocrine Tumor; Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
Intervention: Drug: AMG 479
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; H. Lee Moffitt Cancer Center and Research Institute; Amgen
Recruiting - verified March 2010
Condition: Castleman's Disease
Interventions: Other: Placebo; Drug: CNTO 328
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Arthritis, Rheumatoid
Intervention: Drug: CP 690,550 oral solutions
Sponsor: Pfizer
Not yet recruiting - verified February 2010
Condition: Hodgkin Lymphoma
Intervention: Drug: Everolimus (RAD001)
Sponsor: Novartis
Recruiting - verified March 2010
Condition: Insomnia
Interventions: Drug: MK4305; Drug: Comparator: Placebo to MK4305
Sponsor: Merck
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir (SCH 503034); Drug: erythropoietin; Biological: Peginterferon alfa-2b (SCH 54031); Drug: Ribavirin (SCH 18908)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Osteoarthritis Knee Pain
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF/GW642444 Inhalation Powder; Drug: GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Combivent Respimat; Drug: Combivent CFC-MDI; Drug: Atrovent HFA + Albuterol HFA
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Influenza A Virus, H1N1 Subtype; Influenza B Virus; Influenza, Human; Influenza, Seasonal
Intervention: Drug: zanamivir aqueous solution
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Intervention: Drug: STA 9090
Sponsor: Synta Pharmaceuticals Corp.
Recruiting - verified February 2010
Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052; Drug: BMS-650032; Drug: pegylated-interferon-α; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Condition: Arthritis, Psoriatic
Interventions: Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Active Rheumatoid Arthritis
Intervention: Drug: SBI-087
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tociliumab; Drug: methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Amyloidosis
Intervention: Drug: Bortezomib (Velcade) and Dexamethasone
Sponsors: Boston Medical Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Gastrointestinal Cancer
Interventions: Drug: RAD001; Drug: AV-951
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Novartis; AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: Southern blotting; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Alcohol Dependence
Intervention: Behavioral: Addiction CHESS
Sponsors: University of Wisconsin, Madison; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified March 2010
Condition: Abdominal Pain Upper
Interventions: Drug: REGN475/SAR164877; Drug: Placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified February 2010
Conditions: Graft-Versus-Host Disease; Immune System Disorders
Interventions: Drug: Mycophenolate Mofetil; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Newtwork (BMT CTN)
Recruiting - verified March 2010
Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Keryx / AOI Pharmaceuticals, Inc.; Dana-Farber Cancer Institute
Recruiting - verified March 2010
Conditions: Haemophilus Influenzae Type B Related Disease; Pneumonia; Meningitis; Cellulitis; Osteomyelitis; Epiglottis
Interventions: Biological: InfanrixTM; Biological: GSK Biologicals' Haemophilus inluenzae type b vaccine (GSK 208108); Biological: ActHIBTM; Biological: PentacelTM; Biological: PediarixTM; Biological: PrevnarTM; Biological: RotarixTM; Biological: EngerixTM-B
Sponsor: GlaxoSmithKline
Not yet recruiting - verified March 2010
Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Acute Coronary Syndrome; Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease
Interventions: Drug: Darapladib 160 mg; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Sickle Cell Disease
Interventions: Other: High Demand / Low Infusion; Other: PCA Dosing Plan
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Condition: Cystitis, Interstitial
Interventions: Biological: Tanezumab; Biological: Tanezumab; Biological: Tanezumab; Biological: Tanezumab; Other: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Active Plaque Psoriasis
Interventions: Drug: VB-201; Drug: VB-201; Other: Placebo
Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics
Recruiting - verified March 2010
Conditions: Colonic Polyps; Colonic Neoplasms
Intervention: Device: CT colonography and optical colonoscopy
Sponsor: Japanese CT Colonography Society
Recruiting - verified October 2009
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified March 2010
Condition: Psoriasis
Interventions: Drug: Etanercept ONLY; Drug: Methotrexate and Etanercept
Sponsors: Amgen; Immunex Corporation
Recruiting - verified March 2010
Condition: Acromegaly
Intervention: Drug: BIM 23A760
Sponsor: Ipsen
Recruiting - verified March 2010
Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip
Interventions: Other: Tanezumab 2.5 mg; Other: Tanezumab 5 mg; Other: Tanezumab 10 mg
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Dexamethasone USP Micronized; Drug: Prednisone
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Conditions: HIV Infections; Hepatitis C Virus
Interventions: Drug: Nitazoxanide (NTZ); Drug: Peginterferon alfa-2a (PEG-INF); Drug: Ribavirin (RBV)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified October 2009
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Device: ROX Anastomotic Coupler System (ACS)
Sponsor: ROX Medical, Inc.
Recruiting - verified March 2010
Conditions: Stage IV Breast Cancer; Central Nervous System Involvement/Metastases; Leptomeningeal Metastases; Recurrent Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: methotrexate; Drug: liposomal cytarabine; Other: quality-of-life assessment; Other: questionnaire administration
Sponsor: Fred Hutchinson Cancer Research Center
Recruiting - verified February 2010
Condition: Restless Legs Syndrome
Interventions: Drug: pregabalin; Drug: placebo; Drug: pramipexole
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Lymphoblastic Leukemia, Acute, Childhood
Intervention: Drug: Clofarabine incorporated into a 5-drug regimen
Sponsor: Genzyme
Recruiting - verified October 2009
Condition: Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: oxycodone; Other: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Pain; Back Pain; Low Back Pain; Back Pain With Radiation
Interventions: Drug: Oxycodone IR; Drug: NUCYNTA
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal
Recruiting - verified February 2010
Condition: Thyroid Neoplasm
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Onyx Pharmaceuticals
Recruiting - verified March 2010
Conditions: Hepatitis C; HIV Infections
Interventions: Drug: telaprevir or matching placebo; Drug: telaprevir or matching placebo; Biological: peginterferon alfa-2a; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Drug: Raltegravir (RAL); Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Tenofovir (TDF); Drug: Etravirine (ETV); Drug: Darunavir (DRV); Drug: Maraviroc (MVC); Drug: Lopinavir/ritonavir (LPV/r)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2009
Condition: Pain
Intervention: Drug: oxycodone immediate release (OXYRX)
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Condition: Coronary Artery Disease
Interventions: Drug: Placebo & Aspirin; Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
Sponsors: Harvard Clinical Research Institute; Abbott; Boston Scientific Corporation; Bristol-Myers Squibb; Sanofi-Synthelabo; Cordis Corporation; Eli Lilly and Company; Daiichi Sankyo Inc.; Medtronic
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin glargine + preprandial lispro insulin; Biological: albiglutide + insulin glargine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Gastroesophageal Reflux Disease
Interventions: Drug: arbaclofen placarbil; Drug: Placebo
Sponsor: XenoPort, Inc.
Recruiting - verified March 2010
Conditions: Schizophrenia; Schizoaffective Disorder
Interventions: Drug: Amantadine Hydrochloride, USP; Drug: Amantadine Hydrochloride, USP; Drug: Placebo
Sponsors: North Suffolk Mental Health Association; Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified September 2009
Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsor: Medivation, Inc.
Recruiting - verified March 2010
Condition: Severe Nodular Acne
Intervention: Drug: CIP-Isotretinoin and Isotretinoin
Sponsor: Cipher Pharmaceuticals Inc.
Recruiting - verified February 2010
Conditions: Rectal Cancer; Breast Cancer; Lung Cancer
Intervention:
Sponsors: Dana-Farber Cancer Institute; American Society of Clinical Oncology
Recruiting - verified March 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: placebo; Biological: golimumab; Biological: golimumab; Biological: golimumab
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Condition: Gastroesophageal Reflux
Interventions: Drug: Rabeprazole sodium capsules; Drug: placebo; Drug: Rabeprazole sodium capsules
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type II
Interventions: Drug: Placebo; Drug: Dutogliptin
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Asthma
Interventions: Biological: MEDI-528; Biological: MEDI-528; Biological: MEDI-528; Other: Placebo
Sponsor: MedImmune LLC
Recruiting - verified March 2010
Conditions: Fibromyalgia, Primary; Fibromyalgia, Secondary
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Pain; Neuralgia, Postherpetic; Neuralgia; Mononeuropathies
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Paroxysmal Atrial Fibrillation
Interventions: Procedure: Atrial Fibrillation ablation procedure; Device: NAVISTAR THERMOCOOL and NAVISTAR EZ STEER THERMOCOOL
Sponsor: Biosense Webster, Inc.
Recruiting - verified February 2010
Condition: Systemic Lupus Erythematosus
Interventions: Drug: placebo; Drug: rontalizumab
Sponsor: Genentech
Recruiting - verified February 2010
Condition: Dyslipidemia
Interventions: Drug: ER niacin (+) laropiprant (ERN/LRPT); Drug: Comparator: ER niacin (+) laropiprant (ERN/LRPT); Drug: Comparator: Extended-release niacin (ERN); Drug: Comparator: Placebo to ERN/LRPT
Sponsor: Merck
Recruiting - verified March 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: TOK-001; Drug: TOK-001; Drug: TOK-001
Sponsor: Tokai Pharmaceuticals
Recruiting - verified February 2010
Conditions: Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma
Interventions: Drug: XL184; Drug: temozolomide; Drug: temozolomide; Radiation: Radiation Therapy; Drug: temozolomide
Sponsor: Exelixis
Recruiting - verified March 2010
Condition: Treatment Resistant Depression
Interventions: Drug: Olanzapine and Fluoxetine combination; Drug: Fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Seasonal Influenza; Cough; Sore Throat; Nasal Congestion; Myalgia; Headache; Fatigue
Interventions: Drug: Peramivir; Drug: Peramivir
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified March 2010
Condition: HIV Infections
Intervention: Drug: Highly active antiretroviral therapy (HAART)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
Condition: Partial Epilepsies
Intervention: Drug: Lacosamide
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Condition: Gaucher Disease, Type 1
Intervention: Drug: velaglucerase alfa
Sponsor: Shire Human Genetic Therapies, Inc.
Available - verified March 2010
Condition: Hepatitis C
Intervention: Drug: Infergen with or without ribavirin
Sponsor: Three Rivers Pharmaceuticals
Recruiting - verified March 2010
Condition: Haemophilia A or B With Inhibitors
Interventions: Drug: activated recombinant human factor VII, long acting; Drug: activated recombinant human factor VII, long acting; Drug: activated recombinant human factor VII, long acting
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: paclitaxel; Drug: pertuzumab; Drug: trastuzumab-MCC-DM1
Sponsor: Genentech
Recruiting - verified February 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Sickle Cell Disease; Secretory Phospholipase A2; sPLA2
Interventions: Biological: Single blood transfusion; Behavioral: Standard care
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type II
Interventions: Drug: Dutogliptin; Drug: Placebo
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
Condition: Asthma
Intervention: Drug: JNJ39758979
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cervical Disc Disease
Intervention: Device: Zero-P PEEK
Sponsor: Synthes Spine
Recruiting - verified March 2010
Conditions: Amenorrhea; Female Athlete Triad Syndrome
Interventions: Drug: Transdermal 17Beta-estradiol, progesterone; Drug: Ethinyl Estradiol + Desogestrel; Dietary Supplement: Elemental Calcium and Vitamin D
Sponsors: Massachusetts General Hospital; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: liraglutide; Drug: placebo; Drug: liraglutide; Drug: placebo
Sponsor: Novo Nordisk
Recruiting - verified February 2010
Condition: Glioblastoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: temozolomide; Radiation: Radiation therapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; The Indiana University Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2010
Condition: Tumors
Intervention: Drug: PKI-587
Sponsor: Wyeth
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: MET tyrosine kinase inhibitor PF-02341066; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: QMF149 Twisthaler®; Drug: Mometasone Twisthaler®
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Aneurysmal Subarachnoid Hemorrhage
Interventions: Drug: Clazosentan; Drug: Clazosentan; Drug: Placebo
Sponsor: Actelion
Recruiting - verified March 2010
Conditions: Neuropathic Pain; Mechanical Hypersensitivity
Interventions: Drug: AZD2066; Drug: Placebo
Sponsors: AstraZeneca; Quintiles
Recruiting - verified March 2010
Condition: Alzheimer's Disease
Intervention: Drug: Dimebon
Sponsors: Pfizer; Medivation, Inc.
Recruiting - verified March 2010
Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg; Drug: Sham
Sponsors: Regeneron Pharmaceuticals; Bayer
Recruiting - verified February 2010
Condition: Oral Mucositis
Interventions: Biological: AG013; Biological: AG013; Biological: AG013; Other: Placebo; Other: Placebo; Other: Placebo
Sponsor: ActoGeniX N.V.
Recruiting - verified February 2010
Condition: Postmenopausal Osteoporosis
Interventions: Drug: Ibandronate; Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Neoplasms; Unresectable Metastatic Cutaneous Melanoma
Intervention: Biological: Immunotherapeutic GSK2132231A
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Amyloid Cardiomyopathy
Intervention: Drug: Fx-1006A
Sponsor: FoldRx Pharmaceuticals
Recruiting - verified February 2010
Condition: Schizophrenia
Interventions: Drug: oral risperidone; Drug: paliperidone palmitate
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Conditions: Primary Myelofibrosis; Post-Polycythemia Vera; Post-Essential Thrombocytopenia
Interventions: Drug: Panobinostat; Drug: Panobinostat
Sponsor: Novartis
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: HIV
Interventions: Drug: atazanavir/raltegravir; Drug: atazanavir/raltegravir; Drug: atazanavir/tenofovir/emtricitabine
Sponsor: Community Research Initiative of New England
Recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Adalimumab
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Condition: Alzheimer's Disease
Interventions: Drug: PF-04447943; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: Placebo; Drug: OROS MPH
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride; Drug: Placebo
Sponsor: Amicus Therapeutics
Recruiting - verified March 2010
Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg; Biological: Tanezumab 10 mg
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate plus leuprolide acetate plus prednisone; Drug: leuprolide acetate
Sponsor: Cougar Biotechnology, Inc.
Recruiting - verified March 2010
Condition: Adrenocortical Carcinoma (ACC)
Interventions: Drug: OSI-906; Other: Placebo
Sponsor: OSI Pharmaceuticals
Recruiting - verified August 2009
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Teplizumab (MGA031); Drug: Placebo
Sponsors: MacroGenics; Eli Lilly and Company
Recruiting - verified March 2010
Condition: Herpes Zoster in Autologous Hematopoietic Stem Cell Transplantation Recipients
Interventions: Biological: Herpes Zoster Vaccine 1437173A; Biological: Placebo vaccine (saline)
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Hepatitis C
Intervention:
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified March 2010
Condition: Hereditary Angioedema
Interventions: Drug: Icatibant; Drug: Placebo
Sponsors: Jerini AG; Shire Human Genetic Therapies, Inc.
Recruiting - verified November 2009
Condition: Ovarian Neoplasms
Interventions: Biological: IMC-3G3; Drug: liposomal doxorubicin
Sponsor: ImClone LLC
Recruiting - verified February 2010
Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Alzheimer Disease
Interventions: Drug: Dimebon 20 mg po TID; Drug: Placebo po TID
Sponsors: Pfizer; Medivation, Inc.
Recruiting - verified March 2010
Condition: Multiple Myeloma
Interventions: Drug: 328 plus VMP (Part 1, Part 2-Arm A); Drug: VMP Alone (Part 2-Arm B)
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Duke University; St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified February 2010
Condition: Venous Leg Ulcer
Interventions: Device: Dermagraft(R); Device: Profore
Sponsor: Advanced BioHealing, Inc.
Recruiting - verified February 2010
Condition: Pseudomonas Infection
Intervention: Drug: Ciprofloxacin (Cipro, BAYQ3939)
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: placebo
Sponsor: Wyeth
Recruiting - verified February 2010
Conditions: Parenteral Nutrition Associated Liver Disease; Short Bowel Syndrome
Intervention: Drug: Omegaven™
Sponsor: Children's Hospital Boston
Recruiting - verified February 2010
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Aphasia; Stroke; Cerebrovascular Accident; Apoplexy; Cerebral Infarction
Interventions: Behavioral: Melodic Intonation Therapy; Behavioral: Speech-Repetition-Therapy
Sponsors: Beth Israel Deaconess Medical Center; National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting - verified March 2010
Condition: Hypertension
Intervention: Other: Interactive Spaced Education (ISE) --- online education
Sponsor: Department of Veterans Affairs
Not yet recruiting - verified February 2010
Conditions: Advanced Myelodysplastic Syndrome; Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia After MDS; Thrombocytopenia
Interventions: Drug: eltrombopag olamine; Other: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Cystic Fibrosis
Interventions: Drug: SB656933; Drug: Placebo; Drug: SB656933
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors: Bayer; Onyx Pharmaceuticals; OSI Pharmaceuticals; Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: QTI571; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Conditions: Arterial Occlusive Diseases; Coronary Disease; Heart Diseases; Myocardial Ischemia; Vascular Diseases; Arteriosclerosis; Ischemia; Coronary Artery Disease
Intervention: Procedure: 320 Volume Detector Computed Tomography
Sponsors: Johns Hopkins University; Toshiba America Medical Systems, Inc.
Recruiting - verified November 2009
Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: high performance liquid chromatography; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Glioblastoma Multiforme
Intervention: Drug: Azixa
Sponsor: Myriad Pharmaceuticals
Recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Systemic Juvenile Idiopathic Arthritis
Intervention: Drug: Canakinumab
Sponsors: Novartis Pharmaceuticals; PRINTO / PRCSG
Recruiting - verified August 2009
Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonneoplastic Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Condition: Non Small Cell Lung Cancer
Interventions: Drug: AZD6244; Drug: docetaxel; Drug: Placebo
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Solid Tumor
Interventions: Drug: ABT-263; Drug: gemcitabine
Sponsors: Abbott; Genentech
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified March 2010
Condition: Pulmonary Hypertension
Intervention: Drug: UT-15C
Sponsor: United Therapeutics
Recruiting - verified February 2010
Condition: Systemic Juvenile Idiopathic Arthritis
Interventions: Drug: Canakinumab; Drug: Placebo
Sponsors: Novartis Pharmaceuticals; PRINTO / PRCSG
Recruiting - verified August 2009
Conditions: Advanced Solid Cancers; Metastatic Cancer
Intervention: Drug: Cdc7-inhibitor
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified October 2009
Condition: Systemic Juvenile Idiopathic Arthritis With Active Flare
Interventions: Drug: Canakinumab; Drug: Placebo
Sponsors: Novartis Pharmaceuticals; PRINTO / PRCSG
Recruiting - verified December 2009
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Depression
Interventions: Other: Placebo; Drug: orvepitant
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Conditions: Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension
Intervention: Drug: Ambrisentan or placebo
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Bosutinib; Drug: Letrozole
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Myocardial Infarction
Interventions: Drug: Prochymal®; Drug: Placebo
Sponsor: Osiris Therapeutics
Recruiting - verified March 2010
Conditions: Neoplasms by Histologic Type; Leukemia, Lymphoid; Leukemia, T-Cell; Solid Tumors
Intervention: Drug: PF-03084014
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Euvolemic Hyponatremia
Interventions: Drug: Lixivaptan; Drug: Placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC; Biogen Idec
Recruiting - verified March 2010
Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 10 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 5 mg IV; Drug: Placebo for naproxen; Biological: Placebo for tanezumab; Drug: Naproxen; Biological: Placebo for tanezumab; Drug: Placebo for naproxen
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Cardiovascular Disease; Type 2 Diabetes Mellitus
Interventions: Drug: pioglitazone; Drug: placebo; Dietary Supplement: vitamin D; Dietary Supplement: placebo; Drug: rosiglitazone
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Conditions: Coronary Artery Bypass; Myocardial Infarction; Ventricular Dysfunction, Left; Stroke; Cardiopulmonary Bypass
Interventions: Drug: Acadesine; Drug: Normal Saline
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Diabetic Neuropathies
Interventions: Drug: Carisbamate 800 mg/d; Drug: Pregabalin 300 mg/d; Drug: Placebo; Drug: Carisbamate 1,200 mg/d
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Lymphoma, B-Cell; Lymphoma, Diffuse
Interventions: Drug: inotuzumab ozogamicin (CMC-544); Drug: rituximab
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: imatinib mesylate
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Behcet Syndrome
Interventions: Drug: Apremilast (CC-10004); Drug: Placebo
Sponsor: Celgene Corporation
Recruiting - verified March 2010
Conditions: Actinic Keratoses; Skin Neoplasms
Interventions: Drug: Aminolevulinic Acid; Other: Vehicle
Sponsor: DUSA Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate; Procedure: standard follow-up care
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Everolimus, Exemestane; Drug: Placebo, Exemestane
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Post-Traumatic Stress Disorder
Intervention: Other: Written Disclosure
Sponsor: National Institute of Mental Health (NIMH)
Recruiting - verified April 2009
Conditions: HIV Infections; Peripheral Neuropathy
Interventions: Drug: Duloxetine; Drug: Duloxetine placebo; Drug: Methadone; Drug: Methadone placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
Condition: Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Malignant Glioma
Interventions: Drug: LBH589; Drug: bevacizumab
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Genentech; Novartis
Recruiting - verified March 2010
Conditions: Non-small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Alogliptin and metformin; Drug: Alogliptin and metformin; Drug: Glipizide and metformin
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: HIV; HIV Infections; Pregnancy
Interventions: Drug: TMC114 (darunavir); Drug: TMC125 (etravirine); Drug: TMC114r (ritonavir)
Sponsors: Tibotec, Inc; Tibotec Therapeutics, a Division of Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: CP 690,550; Drug: CP-690,550; Other: Placebo; Other: Placebo; Biological: Biologic TNFi
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Hypertension, Pulmonary
Interventions: Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: placebo; Drug: sildenafil
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Hypertension
Interventions: Drug: Aliskiren; Drug: Aliskiren; Drug: Comparator: Losartan; Drug: Comparator: Placebo to Aliskiren; Drug: Comparator: Placebo to Losartan
Sponsor: Merck
Recruiting - verified March 2010
Condition: Advanced Renal Cell Carcinoma
Interventions: Drug: AMG386; Drug: Sunitinib
Sponsor: Amgen
Recruiting - verified February 2010
Conditions: Herpes Zoster; HIV Infections
Interventions: Biological: Zoster Vaccine Live; Biological: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Adult AIDS Clinical Trials Group; Merck
Recruiting - verified May 2009
Conditions: HIV Infections; Treatment Naive
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
Condition: Major Depressive Disorder
Interventions: Drug: duloxetine; Drug: Placebo; Drug: fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Psoriasis
Interventions: Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 subcutaneous injection
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Polymyalgia Rheumatica; Rheumatoid Arthritis; Rheumatic Disease
Intervention:
Sponsor: Lahey Clinic
Recruiting - verified March 2010
Conditions: Gastroparesis; Diabetic Gastroparesis; Diabetes; Diabetes Mellitus; Delayed Gastric Emptying
Interventions: Drug: metoclopramide; Drug: Placebo
Sponsor: Evoke Pharma
Recruiting - verified March 2010
Condition: Systemic Sclerosis
Intervention: Drug: treprostinil diethanolamine
Sponsor: United Therapeutics
Not yet recruiting - verified February 2009
Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007/Gemcitabine; Drug: Gemcitabine
Sponsor: Abraxis BioScience Inc.
Recruiting - verified December 2009
Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Colon Cancer; Rectal Cancer
Interventions: Biological: Cetuximab; Drug: Irinotecan; Biological: IMC-A12
Sponsors: ImClone LLC; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified February 2010
Condition: Refractory Hematologic Cancer
Interventions: Drug: Cdc7-inhibitor (BMS-863233); Drug: Cdc7-inhibitor (BMS-863233)
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified October 2009
Conditions: Smoking Cessation; Smoking; Tobacco Cessation
Interventions: Biological: NicVAX vaccine; Biological: Placebo vaccine
Sponsors: Nabi Biopharmaceuticals; National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2010
Conditions: Metastatic; Colorectal Cancer
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin); Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Sponsors: Bayer; Onyx Pharmaceuticals
Recruiting - verified February 2010
Condition: Carcinoma, Renal Cell
Interventions: Drug: axitinib; Drug: axitinib; Drug: axitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified October 2009
Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Myocardial Infarction; Angina; Coronary Artery Disease; Myocardial Ischemia
Intervention: Device: Intravascular Near Infrared Spectroscopy
Sponsor: InfraReDx
Recruiting - verified February 2010
Condition: Parkinson Disease
Interventions: Drug: Placebo; Drug: inosine; Drug: inosine
Sponsors: The Parkinson Study Group; Massachusetts General Hospital; Harvard School of Public Health; University of Rochester; Michael J. Fox Foundation for Parkinson's Research
Recruiting - verified March 2010
Conditions: Arthritis; Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Cetuximab; Drug: Paclitaxel; Drug: Carboplatin; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: Accelerated Community Oncology Research Network; ImClone LLC; Advanced Clinical Trial Solutions, LLC
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Biological: aflibercept; Drug: topotecan hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Human Immunodeficiency Virus-1
Interventions: Drug: maraviroc; Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Multiple Sclerosis
Intervention: Other: Single-Use Autoinjector with a Pre-Filled Liquid Avonex Syringe
Sponsor: Biogen Idec
Recruiting - verified February 2010
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Biological: Vaccine; Biological: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine; Drug: trastuzumab; Drug: lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: aprepitant; Drug: Comparator: fosaprepitant + aprepitant (Part I); Drug: Comparator: ondansetron; Drug: Comparator: aprepitant (Part IV); Drug: Comparator: aprepitant + fosaprepitant (Part V)
Sponsor: Merck
Recruiting - verified March 2010
Condition: Carcinoma, Non-small Cell
Intervention: Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Ischemia
Interventions: Other: BMS747158; Other: BMS747158
Sponsor: Lantheus Medical Imaging
Recruiting - verified March 2010
Condition: Postoperative Pain
Interventions: Drug: Oxycodone IR; Drug: Tapentadol IR
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal GmbH
Recruiting - verified February 2010
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsor: Bayer
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Raltegravir; Drug: Darunavir; Drug: Ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Bristol-Myers Squibb; Gilead Sciences; Merck; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Recruiting - verified June 2009
Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Condition: Osteoarthritis
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Osteoarthritis; Arthritis
Interventions: Drug: NSAID; Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Drug: NSAID; Biological: tanezumab; Drug: NSAID
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia; Unstable Angina
Intervention: Drug: Rivaroxaban; Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Bayer
Recruiting - verified February 2010
Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Conditions: Breast Cancer; Breast Neoplasms; Breast Tumors; Cancer; Locally Recurrent and Metastatic Breast Cancer; Metastases; Metastatic Cancer; Oncology; Solid Tumors; Tumors
Interventions: Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab; Drug: AMG 386 3 mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 3 mg/kg, Capecitabine and Lapatinib
Sponsor: Amgen
Recruiting - verified February 2010
Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: Folic Acid; Drug: BIBF1120 placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Metastatic Non-small Cell Lung Cancer
Interventions: Drug: CS7017 tablets; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Condition: Idiopathic Restless Legs Syndrome
Interventions: Drug: placebo and pregabalin; Drug: pramipexol; Drug: pramipexol; Drug: Pregabalin; Drug: pramipexol; Drug: pramipexol
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Melanoma
Interventions: Drug: AntiCD137; Drug: AntiCD137; Drug: AntiCD137; Drug: AntiCD137; Drug: AntiCD137; Drug: Ipilimumab
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified November 2009
Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124); Drug: Placebo
Sponsors: PTC Therapeutics; Genzyme; Cystic Fibrosis Foundation
Recruiting - verified March 2010
Conditions: Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease; CV Risk
Interventions: Drug: Darapladib; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Salsalate; Drug: Salsalate Placebo
Sponsors: Joslin Diabetes Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Condition: Solid Tumors
Intervention: Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Advanced Cancer
Interventions: Drug: Capecitabine; Drug: Doxorubicin; Drug: Ixabepilone; Drug: Docetaxel; Drug: Paclitaxel; Drug: Brivanib alaninate
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Resected Stage III Melanoma With Macroscopic Involvement
Interventions: Drug: GSK 2132231A; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Procedure: Echocardiograms; Procedure: Blood Test
Sponsors: M.D. Anderson Cancer Center; Massachusetts General Hospital
Recruiting - verified March 2010
Conditions: PAH; Pulmonary Arterial Hypertension; Pulmonary Hypertension; Sitaxsentan; ETRA
Interventions: Drug: Sitaxsentan; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Soft Tissue Sarcomas; Translocation-Related Sarcomas (TRS)
Intervention: Drug: Trabectedin, ET 743 and Yondelis
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; PharmaMar
Recruiting - verified February 2010
Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; ETRA; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Not yet recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Other: active surveillance
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Tuberous Sclerosis
Interventions: Drug: RAD001 (Everolimus); Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Conditions: Tuberous Sclerosis; Subependymal Giant Cell Astrocytoma
Interventions: Drug: Everolimus (RAD001); Other: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Urothelial Cancer
Intervention: Drug: TKI258
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Conditions: Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Cancer
Intervention: Drug: PF-04554878
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107); Drug: imatinib (STI571)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Crohn's Disease
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Conditions: Rhinitis; Allergic Conjunctivitis
Interventions: Biological: 6 Amb a 1-U; Biological: 12 Amb a 1-U; Biological: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic
Interventions: Drug: maraviroc; Drug: etravirine
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Psychosocial Effects of Cancer and Its Treatment; Sarcoma
Interventions: Other: educational intervention; Other: informational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment; Procedure: standard follow-up care
Sponsors: Tufts Medical Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Advanced Breast Cancer
Interventions: Drug: Bosutinib; Drug: Exemestane
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Phenylketonuria; Hyperphenylalaninaemia
Intervention: Drug: Sapropterin Dihydrochloride
Sponsor: BioMarin Pharmaceutical
Recruiting - verified January 2010
Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Conditions: Cancer; Non-small Cell Lung Cancer
Interventions: Drug: XL765; Drug: erlotinib
Sponsor: Exelixis
Recruiting - verified March 2010
Conditions: Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Systemic Sclerosis; Scleroderma
Interventions: Drug: treprostinil diethanolamine; Drug: placebo
Sponsor: United Therapeutics
Recruiting - verified February 2010
Conditions: Lupus Nephritis; Lupus Erythematosus, Systemic
Interventions: Drug: Abatacept; Drug: cyclophosphamide; Drug: azathioprine; Drug: prednisone; Drug: abatacept placebo; Drug: azathioprine placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: RG1507; Drug: erlotinib [Tarceva]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); Bacchus Vascular; BSN Medical Inc; Genentech; MEDRAD Interventional/Possis; Mid America Heart Institute; Society of Interventional Radiology Foundation; VasCore at Massachusetts General Hospital
Recruiting - verified February 2010
Condition: Chronic Migraine
Interventions: Drug: propranolol LA; Drug: topiramate; Drug: placebo
Sponsors: The EMMES Corporation; National Institute of Neurological Disorders and Stroke (NINDS); Ortho-McNeil Janssen Scientific Affairs, LLC; CRC Operations Center
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: tiotropium 5mcg/day; Drug: tiotropium 5mcg/day
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
Condition: Crohn's Disease
Intervention: Drug: Ustekinumab; CNTO1275
Sponsor: Centocor, Inc.
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: lapatinib ditosylate; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Rhinitis; Allergic Conjunctivitis
Interventions: Biological: 1.5 Amb a 1-U; Biological: 6 Amb a 1-U; Biological: 12 Amb a 1-U; Biological: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Allergic Conjunctivitis
Interventions: Drug: Ketotifen/naphazoline; Drug: Ketotifen/naphazoline and Vehicle; Drug: Ketotifen/naphazoline and Naphazoline; Drug: Ketotifen/naphazoline and Ketotifen; Drug: Ketotifen and Ketotifen/naphazoline; Drug: Ketotifen and Vehicle; Drug: Ketotifen and Naphazoline; Drug: Ketotifen; Drug: Naphazoline and Ketotifen/naphazoline; Drug: Naphazoline and Vehicle; Drug: Naphazoline; Drug: Naphazoline and Ketotifen; Drug: Vehicle and Ketotifen/naphazoline; Drug: Vehicle; Drug: Vehicle and Naphazoline; Drug: Vehicle and Ketotifen
Sponsor: Bausch & Lomb, Inc.
Recruiting - verified February 2010
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: ambrisentan or sugar pill
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: axitinib; Drug: axitinib; Drug: chemotherapy; Drug: axitinib; Drug: chemotherapy
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Melanoma
Interventions: Biological: OncoVEXGM-CSF; Biological: GM-CSF
Sponsor: BioVex Limited
Recruiting - verified March 2010
Condition: Diabetic Macular Edema
Interventions: Drug: Aliskiren; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: HIV Infections
Intervention: Drug: Vicriviroc
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2009
Condition: Healthy
Interventions: Biological: MEDI-559; Other: Placebo; Biological: MEDI-559
Sponsor: MedImmune LLC
Recruiting - verified March 2010
Condition: Epilepsy
Interventions: Behavioral: COPE (Creating Opportunities for Parent Empowerment); Behavioral: Standard education
Sponsors: Children's Hospital Boston; National Institute of Nursing Research (NINR)
Recruiting - verified March 2010
Condition: Scleroderma
Intervention: Drug: dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: RG1507; Drug: Placebo; Drug: RG1507; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Optic Neuropathy, Ischemic
Intervention:
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Intervention:
Sponsors: University of Washington; Canary Foundation; Early Detection Research Network
Recruiting - verified February 2010
Condition: Soft Tissue Sarcoma
Intervention: Drug: PAZOPANIB
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: rhGAD65; Drug: rhGAD65; Drug: Placebo
Sponsor: Diamyd Therapeutics AB
Recruiting - verified March 2010
Condition: Osteosarcoma
Interventions: Drug: AZD0530; Drug: Placebo
Sponsors: Sarcoma Alliance for Research through Collaboration; AstraZeneca
Recruiting - verified February 2010
Condition: Neoplasms
Intervention: Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Ovarian Cancer
Intervention: Biological: bevacizumab
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Myelofibrosis; Myeloproliferative Disorders; Polycythemia Vera; Essential Thrombocythemia
Intervention: Drug: SB1518
Sponsor: S*BIO
Recruiting - verified March 2010
Conditions: Arthritis; Osteoarthritis; Osteoarthritis, Hip
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Biological: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Non Small Cell Lung Cancer
Interventions: Drug: BMS-690514; Drug: Erlotinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Sarcoma
Interventions: Drug: cisplatin; Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: methotrexate; Drug: zoledronic acid; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Chronic Kidney Disease; Secondary Hyperparathyroidism; Chronic Renal Insufficiency; Chronic Renal Failure
Intervention: Drug: CTA018 Injection
Sponsor: Cytochroma Inc.
Recruiting - verified February 2010
Conditions: Fibrosis; Kidney Failure; Renal Insufficiency
Intervention: Procedure: Lab sample drawn for serum chemistry at baseline visit
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: MORAb-009 by IV on Days 1 and 8 every 21 days for 6 cycles.
Sponsor: Morphotek
Recruiting - verified March 2010
Condition: Diabetes Mellitus
Interventions: Drug: Exubera; Other: Randomized diabetes therapy
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung
Interventions: Drug: SCH 727965; Drug: Capecitabine; Drug: Erlotinib
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects
Interventions: Drug: temozolomide; Drug: vorinostat; Procedure: adjuvant therapy; Procedure: cognitive assessment; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2010
Conditions: Metastatic Castration-resistant Prostrate Cancer (mCRPC); Renal Cell Carcinoma (RCC); Malignant Melanoma (MEL); Non-small Cell Lung Cancer (NSCLC)
Intervention: Biological: MDX-1106
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Glioma
Interventions: Drug: TMZ; Drug: BIBW 2992 plus TMZ; Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Type 2 Diabetes
Intervention:
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010
Conditions: Hepatitis B; Liver Transplantation
Intervention: Biological: HepaGam B
Sponsor: Cangene Corporation
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: Standard anti-rheumatic treatment
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Hepatitis C
Interventions: Drug: PF-00868554; Drug: PF-00868554; Drug: PF-00868554; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: IMO-2055; Drug: Cetuximab; Drug: FOLFIRI
Sponsor: EMD Serono
Recruiting - verified March 2010
Condition: Patent Ductus Arteriosus
Intervention: Device: AMPLATZER Duct Occluder II
Sponsor: AGA Medical Corporation
Recruiting - verified March 2010
Condition: Huntington's Disease
Interventions: Drug: Creatine Monohydrate (HD-02); Drug: placebo
Sponsors: Massachusetts General Hospital; University of Rochester; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified March 2010
Condition: Skin Diseases, Infectious
Interventions: Drug: Daptomycin; Drug: Vancomycin, Clindamycin or semi-synthetic Penicillins
Sponsor: Cubist Pharmaceuticals
Recruiting - verified February 2010
Condition: HIV Infections
Interventions: Drug: Highly Active Antiretroviral Therapy (HAART); Other: No treatment
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
Conditions: Sinusitis; Chronic Sinusitis
Interventions: Drug: Bacitracin; Procedure: Nasopore sponge soaked with saline
Sponsor: Lahey Clinic
Recruiting - verified March 2010
Condition: Foot Ulcer, Diabetic
Interventions: Other: Medical Food; Other: Drink mix calorically similar to experimental product
Sponsor: Abbott Nutrition
Recruiting - verified March 2010
Condition: Thyroid Cancer
Interventions: Drug: XL184; Drug: Placebo
Sponsor: Exelixis
Recruiting - verified March 2010
Condition: Melanoma (Skin)
Intervention: Drug: dasatinib
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Diabetic Retinopathy; Diabetes Complications
Interventions: Procedure: Laser Treatment; Drug: PF-04523655 high; Drug: PF-04523655 middle; Drug: PF-04523655 low
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel; Drug: Prasugrel; Drug: Commercially-available Aspirin
Sponsors: Eli Lilly and Company; Daiichi Sankyo Co., Ltd.; Duke University
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: pemetrexed disodium; Drug: sunitinib malate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Conditions: Lumbar Spinal Stenosis; Neurogenic Intermittent Claudication
Interventions: Device: Superion™ Interspinous Spacer; Device: X-STOP® IPD® Device
Sponsor: VertiFlex, Incorporated
Recruiting - verified February 2010
Conditions: Breast Cancer; Osteoporosis
Interventions: Drug: exemestane; Other: biologic sample preservation procedure; Other: physiologic testing; Procedure: dual x-ray absorptometry
Sponsor: NCIC Clinical Trials Group
Recruiting - verified June 2009
Conditions: Nonneoplastic Condition; Sarcoma
Interventions: Drug: anti-VEGF small molecule PTC299; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Genetic: protein expression analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: biopsy
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI); PTC Therapeutics Incorporated
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Conditions: Dyslipidemias; Coronary Heart Disease; Kidney Disease
Interventions: Drug: ABT-335; Drug: Rosuvastatin; Drug: Placebo
Sponsors: Abbott; AstraZeneca
Recruiting - verified February 2010
Condition: Non-cirrhotic Non-alcoholic Steatohepatitis
Interventions: Other: Placebo; Drug: Silymarin; Drug: Silymarin
Sponsors: Madaus Inc; University of Pennsylvania; University of North Carolina; Thomas Jefferson University; Beth Israel Deaconess Medical Center; University of Pittsburgh
Recruiting - verified December 2009
Conditions: Cancer; GCT; Giant Cell Tumor of Bone
Intervention: Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: cilengitide
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Prostatitis; Cystitis, Interstitial; Urinary Bladder, Overactive; Chronic Pelvic Pain Syndrome; Painful Bladder Syndrome
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Children's Hospital Boston
Recruiting - verified March 2010
Condition: Venous Thromboembolism
Interventions: Drug: AVE5026; Drug: Enoxaparin
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Conditions: Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride; Other: pharmacological study
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified January 2010
Conditions: Kidney Cancer; Leukemia; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: dactinomycin; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Neoplasm Metastases
Intervention: Other: Alpha-Gal Glycosphingolipids
Sponsor: University of Massachusetts
Recruiting - verified March 2010
Condition: Metastatic Melanoma
Intervention: Biological: Alpha-Gal Glycosphingolipids
Sponsor: University of Massachusetts
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: bortezomib; Drug: cytarabine; Drug: etoposide phosphate; Drug: idarubicin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Euvolemic Hyponatremia
Interventions: Drug: lixivaptan; Drug: placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC; Biogen Idec
Recruiting - verified March 2010
Conditions: Glioblastoma; Gliosarcoma
Intervention: Drug: Temozolomide
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; University of Pennsylvania; Wake Forest University; Tufts Medical Center; Dartmouth-Hitchcock Medical Center; Schering-Plough
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention:
Sponsor: University of Massachusetts
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: midostaurin; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Solid Tumors
Interventions: Drug: Comparator: MK1775; Drug: Comparator: gemcitabine; Drug: Comparator: cisplatin; Drug: Comparator: carboplatin; Drug: Comparator: MK1775; Drug: Comparator: MK1775; Drug: Comparator: MK1775; Drug: Comparator: MK1775; Drug: Comparator: gemcitabine; Drug: Comparator: cisplatin; Drug: Comparator: carboplatin; Drug: Comparator: gemcitabine; Drug: Comparator: cisplatin; Drug: Comparator: carboplatin
Sponsor: Merck
Recruiting - verified March 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2009
Condition: Chronic Myelogenous Leukemia - Chronic Phase
Intervention: Drug: Nilotinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified March 2010
Condition: High Risk Stage III Melanoma
Interventions: Drug: ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Ocular Safety
Intervention: Drug: Observational Study
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified February 2010
Condition: Cystic Fibrosis
Interventions: Drug: inhaled mannitol; Drug: Placebo comparator
Sponsors: Pharmaxis; ethica Clinical Research Inc.
Recruiting - verified March 2010
Condition: Hepatic Veno-Occlusive Disease
Intervention: Drug: Defibrotide
Sponsor: Gentium SpA
Recruiting - verified February 2010
Condition: TTR-associated Amyloidosis
Intervention: Other: THAOS is a noninterventional patient registry
Sponsor: FoldRx Pharmaceuticals
Recruiting - verified February 2010
Conditions: Coronary Artery Disease; Overweight
Interventions: Drug: Salsalate; Drug: Placebo
Sponsors: Joslin Diabetes Center; Beth Israel Deaconess Medical Center; Tufts Medical Center
Recruiting - verified February 2010
Condition: HIV Infections
Intervention: Biological: Ad26.ENVA.01 HIV-1 vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2008
Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: peginterferon alfa-2a [Pegasys]; Drug: Copegus; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Biological: cixutumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: ambrisentan plus sildenafil or tadalafil
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: Hemophilia A
Interventions: Drug: Recombinant Anti-hemophilic Factor VIII (Kogenate®FS); Drug: Recombinant Anti-hemophilic Factor VIII (Kogenate®FS)
Sponsor: Bayer
Recruiting - verified March 2010
Conditions: MDS; Myelodysplastic Syndromes; Thrombocytopenia
Interventions: Drug: Placebo; Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Condition: Head and Neck Cancer
Interventions: Biological: IMC-A12; Biological: cetuximab
Sponsor: ImClone LLC
Recruiting - verified March 2010
Condition: Epilepsy
Intervention:
Sponsors: Beth Israel Deaconess Medical Center; Newton-Wellesley Hospital; Brigham and Women's Hospital
Recruiting - verified March 2010
Conditions: Pulmonary Disease, Chronic Obstructive; Emphysema; Bronchitis, Chronic
Intervention:
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2009
Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated); Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: lenalidomide
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Infrarenal Abdominal Aortic Aneurysm
Intervention: Device: Anaconda Stent Graft System
Sponsors: Terumo CVS; Vascutek Ltd., Scotland
Recruiting - verified March 2010
Conditions: Crohn's Disease; Ulcerative Colitis; Inflammatory Bowel Diseases
Interventions: Biological: infliximab; Drug: conventional systemic agents; Biological: Biological therapies other than infliximab
Sponsor: Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: letrozole; Drug: tamoxifen citrate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide; Drug: melphalan; Drug: prednisone; Drug: thalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Preterm Delivery; Short Cervix; Short Uterine Cervical Length
Interventions: Drug: progesterone; Drug: placebo
Sponsors: Columbia Laboratories; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2010
Conditions: HIV Infections; Sexually Transmitted Diseases
Intervention: Biological: Quadrivalent human papillomavirus vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified June 2009
Condition: Epilepsy
Intervention: Drug: pregabalin
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: Liquid Certolizumab pegol; Drug: Liquid Certolizumab pegol; Other: Placebo; Drug: Methotrexate
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Condition: Venous Thromboembolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Condition: Vascular Diseases
Interventions: Drug: Placebo + background low to moderate dose statin; Drug: BMS-582949 + Background low to moderate dose statin; Drug: Atorvastatin
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Conditions: Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: memantine hydrochloride; Other: placebo; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Osteoarthritis
Interventions: Drug: SD-6010; Drug: SD-6010; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: docetaxel; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Alzheimer's Disease
Interventions: Drug: PF-04494700; Drug: PF-04494700; Drug: Placebo
Sponsors: Pfizer; Alzheimer's Disease Cooperative Study (ADCS)
Recruiting - verified March 2010
Condition: Variola Major (Smallpox)
Interventions: Biological: MVA-BN; Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Conditions: Diabetes Mellitus; Depression
Interventions: Behavioral: Enhanced treatment as usual plus adherence training; Behavioral: Enhanced treatment as usual plus CBT-AD
Sponsor: National Institute of Mental Health (NIMH)
Recruiting - verified April 2009
Conditions: Brain and Central Nervous System Tumors; Recurrent Glioblastoma Multiforme
Interventions: Drug: CT-322; Drug: irinotecan hydrochloride
Sponsor: Adnexus, A Bristol-Myers Squibb R&D Company
Recruiting - verified March 2010
Condition: Venous Thromboembolism
Interventions: Drug: dabigatran etexilate 150 mg BID; Drug: matching placebo BID
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsor: Department of Veterans Affairs
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Drug: bortezomib; Drug: lenalidomide
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: gemtuzumab ozogamicin; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: pertuzumab; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Dana-Farber Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified December 2008
Condition: Prostate Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: samarium Sm 153 lexidronam pentasodium
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Anal Cancer; Precancerous Condition
Interventions: Drug: cidofovir; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Procedure: biopsy; Procedure: histopathologic examination
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Atopic Dermatitis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Atopic Dermatitis and Vaccinia Network
Recruiting - verified February 2010
Condition: Carcinoma, Non Small Cell Lung
Interventions: Drug: PF-00299804; Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Breast Cancer; Carcinoma of the Breast
Interventions: Drug: Paclitaxel; Drug: Trastuzumab
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Genentech
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Drug: Enfuvirtide; Drug: Raltegravir; Drug: Darunavir; Drug: Tipranavir; Drug: Etravirine; Drug: Maraviroc
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Adult AIDS Clinical Trials Group
Recruiting - verified April 2009
Condition: Glioma
Intervention: Drug: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Neoplasms
Interventions: Drug: RG4733; Drug: RG4733; Drug: RG4733
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Aspergillosis
Interventions: Drug: voriconazole; Drug: anidulafungin; Drug: voriconazole
Sponsors: Pfizer; Mycoses Study Group
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: docetaxel; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Atherosclerosis; Myocardial Ischemia; Myocardial Infarction
Interventions: Drug: SCH 530348; Drug: Placebo
Sponsors: Schering-Plough; Duke University
Recruiting - verified March 2010
Condition: Cancer
Intervention: Drug: PRLX 93936
Sponsor: Prolexys Pharmaceuticals
Recruiting - verified March 2010
Condition: End Stage Renal Disease
Interventions: Device: Symmetric Tip Catheter; Device: Conventional Split-tip Catheter
Sponsor: Tyco Healthcare Group
Recruiting - verified March 2010
Condition: Epilepsies, Partial
Interventions: Drug: pregabalin 600 mg/day; Drug: pregabalin 150 mg/day
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Rotigotine; Other: Placebo
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Conditions: Staphylococcus Aureus; Bacteremia; Mediastinitis
Interventions: Biological: V710; Biological: Comparator: Placebo (unspecified)
Sponsor: Merck
Recruiting - verified March 2010
Condition: Atopic Dermatitis
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: etoposide; Drug: methotrexate; Drug: rasburicase; Drug: sirolimus; Drug: tacrolimus; Other: flow cytometry; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsor: Massachusetts General Hospital
Recruiting - verified April 2008
Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Drug: conventional systemic agents; Biological: infliximab; Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab
Sponsor: Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
Condition: Multiple Myeloma
Interventions: Drug: bortezomib, thalidomide, and dexamethasone (VTD); Drug: bortezomib and dexamethasone (VD); Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Conditions: Sepsis; Severe Sepsis; Septic Shock
Interventions: Procedure: Early Goal Directed Therapy (EGDT); Procedure: Protocolized Standard Care (PSC); Procedure: Usual Care (UC)
Sponsors: National Institute of General Medical Sciences (NIGMS); University of Pittsburgh
Recruiting - verified September 2008
Condition: Moderate Risk of CVD
Interventions: Drug: Aspirin (Acetylsalicylic acid, BAYE4465); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Procedure: thoracoscopic surgery; Procedure: videothoracoscopy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: topotecan hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Melanoma
Intervention: Drug: Ipilimumab
Sponsor: Bristol-Myers Squibb
Available - verified March 2010
Condition: Periodic Paralysis
Interventions: Drug: Dichlorphenamide; Drug: Placebo
Sponsors: University of Rochester; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: Gemcitabine; Drug: Sorafenib; Drug: Placebo; Drug: Capecitabine
Sponsors: Accelerated Community Oncology Research Network; Onyx Pharmaceuticals
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin; Other: clinical observation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Schizophrenia; Schizophrenic Disorders; Psychotic Disorders; Dementia Praecox.
Intervention: Drug: Paliperidone ER
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Ulcerative Colitis
Interventions: Biological: golimumab, placebo; Biological: Golimumab, placebo; Biological: Placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Condition: Ulcerative Colitis
Interventions: Biological: Golimumab, placebo; Biological: Golimumab, placebo; Biological: Golimumab, placebo; Biological: Placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Condition: Invasive Breast Cancer
Interventions: Drug: doxorubicin; Drug: cyclophosphamide; Drug: paclitaxel; Drug: trastuzumab; Drug: lapatinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); GlaxoSmithKline
Recruiting - verified February 2010
Condition: HIV Infections
Interventions: Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2009
Condition: Kidney Transplantation
Interventions: Drug: Cyclosporine; Drug: CP-690,550; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: fluorescence in situ hybridization; Genetic: polymorphism analysis; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: ABT-263
Sponsors: Abbott; Genentech
Recruiting - verified January 2010
Condition: Tumor Antigen-positive Non-Small Cell Lung Cancer
Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Biological: Placebo Control
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Childhood Obesity
Interventions: Other: Diet; Other: Diet
Sponsors: Children's Hospital Boston; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Condition: Heart Decompensation
Interventions: Drug: Placebo; Drug: Nesiritide
Sponsor: Scios, Inc.
Recruiting - verified February 2010
Condition: Cytomegalovirus Infections
Interventions: Drug: Placebo; Drug: Valganciclovir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Anemia
Intervention: Drug: Deferasirox
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Leukemia, Lymphocytic, Chronic
Intervention: Drug: alvocidib (HMR1275)
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: AMG 706; Drug: placebo
Sponsors: Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Interventions: Drug: cisplatin + Docetaxel; Drug: Panitumumab
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: etoposide; Drug: sunitinib malate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Otelixizumab
Sponsors: Tolerx Inc.; Juvenile Diabetes Research Foundation
Recruiting - verified June 2009
Condition: Lung Cancer
Interventions: Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Multiple Sclerosis; Transverse Myelitis; Neuromyelitis Optica; Acute Disseminated Encephalomyelitis; Optic Neuritis
Intervention:
Sponsor: Accelerated Cure Project for Multiple Sclerosis
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Glioblastoma Multiforme; Gliosarcoma
Interventions: Drug: ZD6474; Drug: temozolomide; Radiation: Radiation Therapy
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; University of Virginia; Memorial Sloan-Kettering Cancer Center; Henry Ford Hospital
Recruiting - verified March 2010
Condition: Pulmonary Embolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin followed by VKA
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Anemia; Chronic Kidney Disease; Kidney Disease
Interventions: Drug: darbepoetin alfa QW; Drug: darbepoetin alfa Q2W
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Cognitive/Functional Effects; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Genetic: microarray analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: cognitive assessment; Procedure: diffusion tensor imaging; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Thoracic Aortic Aneurysms
Intervention: Device: Relay Thoracic Stent-Graft
Sponsor: Bolton Medical
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin hydrochloride; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: bosentan; Drug: bosentan and sildenafil combination
Sponsor: Actelion
Recruiting - verified February 2010
Condition: Systemic Lupus Erythematosus
Interventions: Drug: steroids (prednisone or prednisolone) + MMF; Drug: abatacept; Drug: abatacept
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Lung Cancer
Intervention: Drug: IPI-504
Sponsor: Infinity Pharmaceuticals
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: HIV Infections
Intervention: Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine/Fluorouracil with External Beam Radiation
Sponsor: University of Massachusetts
Recruiting - verified March 2010
Condition: Lung Cancer
Intervention: Drug: Bortezomib
Sponsors: University of Massachusetts; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: dasatinib; Genetic: gene expression analysis; Genetic: mutation analysis; Other: immunohistochemistry staining method; Other: immunologic technique; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study; Procedure: biopsy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Hepatitis B, Chronic
Intervention: Drug: Entecavir
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Conditions: Cancer; Colon Cancer; Colorectal Cancer; Metastatic Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: FOLFIRI - Panitumumab; Drug: FOLFIRI - Bevacizumab
Sponsor: Amgen
Recruiting - verified February 2010
Condition: Leukemia
Interventions: Biological: filgrastim; Drug: busulfan; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: decitabine; Drug: etoposide; Genetic: cytogenetic analysis; Procedure: autologous bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: fluvastatin sodium; Other: clinical observation
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Prostate Cancer
Interventions: Other: internet-based intervention; Procedure: assessment of therapy complications
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Arthritis, Rheumatoid
Intervention: Other: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Atrial Fibrillation; Atrial Flutter
Interventions: Drug: warfarin; Drug: apixaban
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Breast Cancer; Metastatic Cancer
Intervention: Drug: dasatinib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Benign Prostatic Hyperplasia (BPH)
Intervention: Device: Prolieve® Thermodilatation System
Sponsor: Boston Scientific Corporation
Recruiting - verified February 2010
Conditions: Vesico-Ureteral Reflux; Urinary Tract Infections
Interventions: Drug: Trimethoprim-Sulfamethoxazole; Drug: Placebo
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: liposomal cytarabine; Drug: methotrexate; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: lapatinib ditosylate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lupus Nephritis
Interventions: Drug: mycophenolate mofetil [CellCept]; Drug: Cyclophosphamide; Drug: mycophenolate mofetil [CellCept]; Drug: Azathioprine
Sponsors: Hoffmann-La Roche; Aspreva Pharmaceuticals
Recruiting - verified February 2010
Condition: Osteoarthritis
Interventions: Drug: Celecoxib; Drug: Any commercially available NSAID with the indication for osteoarthritis
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: mitoxantrone hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Neoplasms
Interventions: Drug: CP-751,871 + exemestane; Drug: exemestane
Sponsors: Pfizer; Massachusetts General Hospital
Recruiting - verified March 2010
Condition: Hepatitis B Infection
Intervention: Drug: Entecavir
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: thioguanine
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Pain; Prostate Cancer
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: calcium glucarate; Dietary Supplement: vitamin D; Drug: calcium gluconate; Drug: zoledronic acid; Radiation: samarium Sm 153 lexidronam pentasodium; Radiation: strontium chloride Sr 89
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: HIV-1
Intervention: Drug: TMC125
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Kallmann's Syndrome; Hypogonadotropic Hypogonadism; Healthy Volunteers
Interventions: Drug: Letrozole; Drug: NAL-GLU GnRH antagonist; Drug: GnRH
Sponsors: Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified February 2010
All Locations ... United States » ... Massachusetts » ... Lynn 
